{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:06:21Z","timestamp":1791864381635,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIDDK Diabetic Complications Consortium","award":["DK076169"],"award-info":[{"award-number":["DK076169"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01-HL55782"],"award-info":[{"award-number":["P01-HL55782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 RR017677"],"award-info":[{"award-number":["P20 RR017677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12017-016-8423-9","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T12:54:50Z","timestamp":1467896090000},"page":"46-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study"],"prefix":"10.1007","volume":"19","author":[{"name":"DCCT\/EDIC Group of Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-2542","authenticated-orcid":false,"given":"Samar M.","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad M.","family":"El Abiad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanka D.","family":"Spassieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rembiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Bielawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Lopes-Virella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"8423_CR1","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-08-1167","volume":"8","author":"RD Baird","year":"2009","unstructured":"Baird, R. D., Kitzen, J., Clarke, P. A., Planting, A., Reade, S., Reid, A., et al. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics, \n                           8, 1430\u20131437.","journal-title":"Molecular Cancer Therapeutics"},{"key":"8423_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85817","volume":"27","author":"K Bejaoui","year":"2001","unstructured":"Bejaoui, K., Wu, C., Scheffler, M. D., Haan, G., Ashby, P., Wu, L., et al. (2001). SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nature Genetics, \n                           27, 261\u2013262.","journal-title":"Nature Genetics"},{"key":"8423_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1476-511X-9-84","volume":"9","author":"M Bertea","year":"2010","unstructured":"Bertea, M., R\u00fctti, M. F., Othman, A., Marti-Jaun, J., Hersberger, M., von Eckardstein, A., & Hornemann, T. (2010). Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids in Health and Disease, \n                           9, 84.","journal-title":"Lipids in Health and Disease"},{"key":"8423_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-1-60761-322-0_22","volume":"579","author":"J Bielawski","year":"2009","unstructured":"Bielawski, J., Pierce, J. S., Snider, J., Rembiesa, B., Szulc, Z. M., & Bielawska, A. (2009). Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods in Molecular Biology, \n                           579, 443\u2013467.","journal-title":"Methods in Molecular Biology"},{"key":"8423_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/85879","volume":"27","author":"JL Dawkins","year":"2001","unstructured":"Dawkins, J. L., Hulme, D. J., Brahmbhatt, S. B., Auer-Grumbach, M., & Nicholson, G. A. (2001). Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nature Genetics, \n                           27, 309\u2013312.","journal-title":"Nature Genetics"},{"key":"8423_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, \n                           329, 977\u2013986.","journal-title":"New England Journal of Medicine"},{"key":"8423_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/ene.12663","volume":"22","author":"MF Dohrn","year":"2015","unstructured":"Dohrn, M. F., Othman, A., Hirshman, S. K., Bode, H., Alecu, I., F\u00e4hndrich, E., et al. (2015). Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: A susceptibility to neuropathy? European Journal of Neurology, \n                           22, 806\u2013814.","journal-title":"European Journal of Neurology"},{"key":"8423_CR8","doi-asserted-by":"publisher","first-page":"15380","DOI":"10.1074\/jbc.R115.658823","volume":"290","author":"J Duan","year":"2015","unstructured":"Duan, J., & Merrill, A. H, Jr. (2015). 1-Deoxysphingolipids encountered exogenously and made de novo: Dangerous mysteries inside an enigma. Journal of Biological Chemistry, \n                           290, 15380\u201315389.","journal-title":"Journal of Biological Chemistry"},{"key":"8423_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1212\/WNL.36.10.1300","volume":"36","author":"PJ Dyck","year":"1986","unstructured":"Dyck, P. J., Karnes, J., O\u2019Brien, P. C., & Swanson, C. J. (1986). Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, \n                           36, 1300\u20131308.","journal-title":"Neurology"},{"key":"8423_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2337\/diacare.22.1.99","volume":"22","author":"Epidemiology of Diabetes Interventions and Complication (EDIC) Research Group","year":"1999","unstructured":"Epidemiology of Diabetes Interventions and Complication (EDIC) Research Group. (1999). Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care, \n                           22, 99\u2013111.","journal-title":"Diabetes Care"},{"key":"8423_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/diacare.17.11.1281","volume":"17","author":"EL Feldman","year":"1994","unstructured":"Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994). A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care, \n                           17, 1281\u20131289.","journal-title":"Diabetes Care"},{"key":"8423_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/978-1-4419-6741-1_14","volume":"688","author":"TE Fox","year":"2010","unstructured":"Fox, T. E., & Kester, M. (2010). Therapeutic strategies for diabetes and complications: A role for sphingolipids? Advances in Experimental Medicine and Biology, \n                           688, 206\u2013216.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"8423_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-511X-12-98","volume":"12","author":"S Galadari","year":"2013","unstructured":"Galadari, S., Rahman, A., Pallichankandy, S., Galadari, A., & Thayyullathil, F. (2013). Role of ceramide in diabetes mellitus: Evidence and mechanisms. Lipids in Health and Disease, \n                           12, 98.","journal-title":"Lipids in Health and Disease"},{"key":"8423_CR14","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1172\/JCI57549","volume":"121","author":"K Garofalo","year":"2011","unstructured":"Garofalo, K., Penno, A., Schmidt, B. P., Lee, H. J., Frosch, M. P., & von Eckardstein, A. (2011). Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. Journal of Clinical Investigation, \n                           121, 4735\u20134745.","journal-title":"Journal of Clinical Investigation"},{"key":"8423_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","volume":"51","author":"S Gr\u00f6sch","year":"2012","unstructured":"Gr\u00f6sch, S., Schiffmann, S., & Geisslinger, G. (2012). Chain length-specific properties of ceramides. Progress in Lipid Research, \n                           51, 50\u201362.","journal-title":"Progress in Lipid Research"},{"key":"8423_CR16","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","volume":"51","author":"SM Hammad","year":"2010","unstructured":"Hammad, S. M., Pierce, J. S., Soodavar, F., Smith, K. J., Al Gadban, M. M., Rembiesa, B., et al. (2010). Blood sphingolipidomics in healthy humans: Impact of sample collection methodology. Journal of Lipid Research, \n                           51, 3074\u20133087.","journal-title":"Journal of Lipid Research"},{"key":"8423_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun, Y. A., & Obeid, L. M. (2008). Principles of bioactive lipid signalling: Lessons from sphingolipids. Nature Review Molecular Cell Biology, \n                           9, 139\u2013150.","journal-title":"Nature Review Molecular Cell Biology"},{"key":"8423_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.biocel.2013.03.012","volume":"45","author":"D Hartmann","year":"2013","unstructured":"Hartmann, D., Wegner, M. S., Wanger, R. A., Ferreir\u00f3s, N., Schreiber, Y., Lucks, J., et al. (2013). The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS. International Journal of Biochemistry & Cell Biology, \n                           45, 1195\u20131203.","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"8423_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1464-5491.2012.03644.x","volume":"29","author":"WH Herman","year":"2012","unstructured":"Herman, W. H., Pop-Busui, R., Braffett, B. H., Martin, C. L., Cleary, P. A., Albers, J. W., et al. (2012). Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: Results from the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications. Diabetic Medicine, \n                           29, 937\u2013944.","journal-title":"Diabetic Medicine"},{"key":"8423_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.metabol.2014.07.001","volume":"63","author":"RL Klein","year":"2014","unstructured":"Klein, R. L., Hammad, S. M., Baker, N. L., Hunt, K. J., Al Gadban, M. M., Cleary, P. A., et al. (2014). Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism, \n                           63, 1287\u20131295.","journal-title":"Metabolism"},{"key":"8423_CR21","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1096\/fj.15-272567","volume":"29","author":"R Kramer","year":"2015","unstructured":"Kramer, R., Bielawski, J., Kistner-Griffin, E., Othman, A., Alecu, I., Ernst, D., et al. (2015). Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB Journal, \n                           29, 4461\u20134472.","journal-title":"FASEB Journal"},{"key":"8423_CR22","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1007\/s10637-011-9772-8","volume":"30","author":"C Massard","year":"2012","unstructured":"Massard, C., Salazar, R., Armand, J. P., Majem, M., Deutsch, E., Garc\u00eda, M., et al. (2012). Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Investigational New Drugs, \n                           30, 2318\u20132326.","journal-title":"Investigational New Drugs"},{"key":"8423_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2337\/db14-1325","volume":"64","author":"A Othman","year":"2015","unstructured":"Othman, A., Bianchi, R., Alecu, I., Wei, Y., Porretta-Serapiglia, C., Lombardi, R., et al. (2015). Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. Diabetes, \n                           64, 1035\u20131045.","journal-title":"Diabetes"},{"key":"8423_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00125-011-2384-1","volume":"55","author":"A Othman","year":"2012","unstructured":"Othman, A., R\u00fctti, M. F., Ernst, D., Saely, C. H., Rein, P., Drexel, H., et al. (2012). Plasma deoxysphingolipids: A novel class of biomarkers for the metabolic syndrome? Diabetologia, \n                           55, 421\u2013431.","journal-title":"Diabetologia"},{"key":"8423_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/hep.26015","volume":"57","author":"JW Park","year":"2013","unstructured":"Park, J. W., Park, W. J., Kuperman, Y., Boura-Halfon, S., Pewzner-Jung, Y., & Futerman, A. H. (2013). Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. Hepatology, \n                           57, 525\u2013532.","journal-title":"Hepatology"},{"key":"8423_CR26","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1074\/jbc.M109.092973","volume":"285","author":"A Penno","year":"2010","unstructured":"Penno, A., Reilly, M. M., Houlden, H., Laur\u00e1, M., Rentsch, K., Niederkofler, V., et al. (2010). Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. Journal of Biological Chemistry, \n                           285, 11178\u201311187.","journal-title":"Journal of Biological Chemistry"},{"key":"8423_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.bbamem.2011.07.023","volume":"1808","author":"SN Pinto","year":"2011","unstructured":"Pinto, S. N., Silva, L. C., Futerman, A. H., & Prieto, M. (2011). Effect of ceramide structure on membrane biophysical properties: The role of acyl chain length and unsaturation. Biochimica Biophysica Acta, \n                           1808, 2753\u20132760.","journal-title":"Biochimica Biophysica Acta"},{"key":"8423_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ajhg.2010.09.010","volume":"87","author":"A Rotthier","year":"2010","unstructured":"Rotthier, A., Auer-Grumbach, M., Janssens, K., Baets, J., Penno, A., Almeida-Souza, L., et al. (2010). Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. American Journal of Human Genetics, \n                           87, 513\u2013522.","journal-title":"American Journal of Human Genetics"},{"key":"8423_CR29","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00280-011-1612-1","volume":"68","author":"P Sch\u00f6ffski","year":"2011","unstructured":"Sch\u00f6ffski, P., Dumez, H., Ruijter, R., Miguel-Lillo, B., Soto-Matos, A., Alfaro, V., & Giaccone, G. (2011). Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: Results of a phase I dose-escalating study in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, \n                           68, 1397\u20131403.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"8423_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1194\/jlr.M022715","volume":"53","author":"LC Silva","year":"2012","unstructured":"Silva, L. C., Ben David, O., Pewzner-Jung, Y., Laviad, E. L., Stiban, J., Bandyopadhyay, S., et al. (2012). Ablation of ceramide synthase 2 strongly affects biophysical properties of membranes. Journal of Lipid Research, \n                           53, 430\u2013436.","journal-title":"Journal of Lipid Research"},{"key":"8423_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1476-511X-13-161","volume":"13","author":"N Wei","year":"2014","unstructured":"Wei, N., Pan, J., Pop-Busui, R., Othman, A., Alecu, I., Hornemann, T., & Eichler, F. S. (2014). Altered sphingoid base profiles in type 1 compared to type 2 diabetes. Lipids in Health and Disease, \n                           13, 161.","journal-title":"Lipids in Health and Disease"},{"key":"8423_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbamem.2008.07.030","volume":"1788","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y., Li, X., Becker, K. A., & Gulbins, E. (2009). Ceramide-enriched membrane domains-structure and function. Biochimca Biophysica Acta, \n                           1788, 178\u2013183.","journal-title":"Biochimca Biophysica Acta"},{"key":"8423_CR33","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bbamem.2006.08.009","volume":"1758","author":"W Zheng","year":"2006","unstructured":"Zheng, W., Kollmeyer, J., Symolon, H., Momin, A., Munter, E., Wang, E., et al. (2006). Ceramides and other bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochimica Biophysica Acta, \n                           1758, 1864\u20131884.","journal-title":"Biochimica Biophysica Acta"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-016-8423-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12017-016-8423-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-016-8423-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-016-8423-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T18:17:54Z","timestamp":1589739474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12017-016-8423-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["8423"],"URL":"https:\/\/doi.org\/10.1007\/s12017-016-8423-9","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"value":"1535-1084","type":"print"},{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]},"assertion":[{"value":"30 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Institutional Review Board (IRB) at the Medical University of South Carolina (MUSC) and all participating DCCT\/EDIC centers approved the sample collection procedures. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}